“Every Breath Counts Coalition” Aims to Help Governments End
Preventable Pneumonia Deaths in a Set of African Countries by 2030
IRVINE, Calif.--(BUSINESS WIRE)--Nov. 13, 2017--
In conjunction with World Pneumonia Day on Sunday, November 12,Masimo (NASDAQ:
MASI) announced its continuing efforts to help combat the global burden
Each year, it is estimated that 178,000 newborns and 773,000 children
die from pneumonia, making it the leading global cause of death in
children under five.1 Increasingly, the major pneumonia
burden is in the first 2 years of life,with the problem
being particularly challenging in low-resource settings such as
It is time for action in eliminating pneumonia. Today Masimo and its
partners in the fight against pneumonia are debuting a documentary
entitled United for Oxygen, examining the problem, available at this
link, and ask for your assistance in spreading the word across the
Along with more than 30 other organizations, including UNICEF, Save the
Children, The Newborn Foundation, The Bill & Melinda Gates Foundation,
The Clinton Health Access Initiative, GSK, and Philips, Masimo is a
founding member of the “Every Breath Counts Coalition,” dedicated to
eliminating all pneumonia-related deaths. Each member of the coalition
brings unique expertise to the problem, with some working on
pneumococcal vaccine coverage, some on access to medical oxygen, others
on education, and, in Masimo’s case, the use of SET® pulse
oximetry, the most accurate and reliable pulse oximetry in the world;4
pulse oximetry is often included in relevant pneumonia clinical
screening protocols. As part of a grant from The Bill & Melinda Gates
Foundation, Masimo has developed Rad-G™, a low-cost pulse oximeter that
can be used as part of pneumonia screening, amongst other applications.
Joe Kiani, Founder and CEO of Masimo, said, “Eliminating pneumonia will
take everyone’s unified efforts. Together we can bend the curve and
eliminate preventable childhood deaths from pneumonia, so no child has
to fight to breathe. How can you help? Join the ‘Every Breath Counts
Rad-G is currently not available for sale in the United States, Canada,
or the E.U.
#Masimo | #EveryBreathCounts | #United4Oxygen | #StopPneumonia |
#NewbornFoundation | #GobeeGroup | #GatesFoundation
1. Miles, Carolyn. Partnering to Fight Pneumonia, The ‘Forgotten Killer’
of Children. Huffington Post. 31 October 2017. https://www.huffingtonpost.com/entry/59f8d6d6e4b0b7f0915f6271.
Walker CL, Rudan I, Liu L, et al. Global burden of childhood pneumonia
and diarrhea. Lancet 2013; 381: 1405–16.
3. Green and
Kolberg. Neonatal pneumonia in sub-Saharan Africa, Pneumonia (2016) 8:3
4. Published clinical studies on
Masimo SET® pulse oximetry can be found at http://www.masimo.com/home/clinical-evidence/masimo-set-pulse-oximetry/.
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. Masimo SET® has also been
shown to help clinicians reduce severe retinopathy of prematurity in
neonates,1 improve CCHD screening in newborns,2
and, when used for continuous monitoring with Masimo Patient SafetyNet™*
in post-surgical wards, reduce rapid response activations and costs.3,4,5
Masimo SET® is estimated to be used on more than 100 million
patients in leading hospitals and other healthcare settings around the
world,6 and is the primary pulse oximetry at 17 of the top 20
hospitals listed in the 2017-18 U.S. News and World Report Best
Hospitals Honor Roll.7 In 2005, Masimo introduced rainbow®
Pulse CO-Oximetry technology, allowing noninvasive and continuous
monitoring of blood constituents that previously could only be measured
invasively, including total hemoglobin (SpHb®), oxygen
content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin
(SpMet®), Pleth Variability Index (PVi®), and more
recently, Oxygen Reserve Index™ (ORi™), in addition to SpO2,
pulse rate, and perfusion index (Pi). In 2014, Masimo introduced Root®,
an intuitive patient monitoring and connectivity platform with the
Masimo Open Connect™ (MOC-9™) interface, enabling other companies to
augment Root with new features and measurement capabilities. Masimo is
also taking an active leadership role in mHealth with products such as
the Radius-7™ wearable patient monitor, iSpO2®
pulse oximeter for smartphones, and the MightySat™ fingertip pulse
oximeter. Additional information about Masimo and its products may be
found at www.masimo.com.
Published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.
ORi has not received FDA 510(k) clearance and is not available for sale
in the United States.
*The use of the trademark Patient SafetyNet
is under license from University HealthSystem Consortium.
1. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm
Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
de-Wahl Granelli A et al. Impact of pulse oximetry screening on the
detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;338.
Taenzer AH et al. Impact of Pulse Oximetry Surveillance on Rescue Events
and Intensive Care Unit Transfers: A Before-And-After Concurrence Study. Anesthesiology.
4. Taenzer AH et al. Postoperative
Monitoring – The Dartmouth Experience. Anesthesia Patient Safety
Foundation Newsletter. Spring-Summer 2012.
5. McGrath SP et al.
Surveillance Monitoring Management for General Care Units: Strategy,
Design, and Implementation. The Joint Commission Journal on Quality
and Patient Safety. 2016 Jul;42(7):293-302.
6. Estimate: Masimo
data on file.
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, among others, statements regarding the potential
effectiveness of Masimo SET® and Rad-G™ These forward-looking
statements are based on current expectations about future events
affecting us and are subject to risks and uncertainties, all of which
are difficult to predict and many of which are beyond our control and
could cause our actual results to differ materially and adversely from
those expressed in our forward-looking statements as a result of various
risk factors, including, but not limited to: risks related to our
assumptions regarding the repeatability of clinical results; risks
related to our belief that Masimo's unique noninvasive measurement
technologies, including Masimo SET® and Rad-G, contribute to
positive clinical outcomes and patient safety; risks related to our
belief that Masimo noninvasive medical breakthroughs provide
cost-effective solutions and unique advantages; as well as other factors
discussed in the "Risk Factors" section of our most recent reports filed
with the Securities and Exchange Commission ("SEC"), which may be
obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171113005491/en/
Evan Lamb, 949-396-3376